{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T09:07:29Z","timestamp":1789722449397,"version":"4.0.1"},"reference-count":98,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jtct.2025.10.025","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T07:34:14Z","timestamp":1761204854000},"page":"277-287","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Who Is Eligible for Chimeric Antigen Receptor T Cell Therapy? Expert Perspectives on Overcoming Referral Barriers"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3365-6562","authenticated-orcid":false,"given":"Mazyar","family":"Shadman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7302-8299","authenticated-orcid":false,"given":"Sairah","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio C.","family":"Chavez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manali","family":"Kamdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5260-1981","authenticated-orcid":false,"given":"Mohamed L.","family":"Sorror","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5910-4571","authenticated-orcid":false,"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua A.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javid","family":"Moslehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Miklos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 1","key":"10.1016\/j.jtct.2025.10.025_bib0001","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/hon.3153","article-title":"CAR T-cell therapy in large B cell lymphoma","volume":"41","author":"Boardman","year":"2023","journal-title":"Hematol Oncol"},{"issue":"10254","key":"10.1016\/j.jtct.2025.10.025_bib0002","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.jtct.2025.10.025_bib0003","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"for the TRANSFORM Investigators. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2025.10.025_bib0004","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(22)00339-4","article-title":"Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study","volume":"23","author":"Sehgal","year":"2022","journal-title":"Lancet Oncol"},{"issue":"10402","key":"10.1016\/j.jtct.2025.10.025_bib0005","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","article-title":"Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study","volume":"402","author":"Siddiqi","year":"2023","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.jtct.2025.10.025_bib0006","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1038\/s41591-024-02986-9","article-title":"Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study","volume":"30","author":"Morschhauser","year":"2024","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.jtct.2025.10.025_bib0007","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1200\/JCO.23.02214","article-title":"Lisocabtagene maraleucel in relapsed\/refractory mantle cell lymphoma: primary analysis of the mantle cell lymphoma cohort from TRANSCEND NHL 001, a phase I multicenter seamless design study","volume":"42","author":"Wang","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2025.10.025_bib0008","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2025.10.025_bib0009","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.jtct.2025.10.025_bib0010","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"All ZUMA-7 Investigators and Contributing Kite Members. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jtct.2025.10.025_bib0011","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.jtct.2025.10.025_bib0012","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2025.10.025_bib0013","series-title":"TECARTUS\u00ae (brexucabtagene autoleucel) [package insert]","year":"2025"},{"issue":"10","key":"10.1016\/j.jtct.2025.10.025_bib0014","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jtct.2023.07.002","article-title":"Updated indications for immune effector cell therapy: 2023 guidelines from the American Society for Transplantation and Cellular Therapy","volume":"29","author":"Kanate","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2025.10.025_bib0015","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1182\/blood-2024-198018","article-title":"Five-year outcomes of patients (pts) with relapsed\/refractory mantle cell lymphoma (R\/R MCL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-2 cohorts 1 and 2","volume":"144","author":"Wang","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2025.10.025_bib0016","article-title":"Real-world outcomes with chimeric antigen receptor T cell therapies in large B cell lymphoma: a systematic review and meta-analysis","volume":"30","author":"Jacobson","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"10.1016\/j.jtct.2025.10.025_bib0017","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jtct.2022.07.011","article-title":"Patterns of use, outcomes, and resource utilization among recipients of commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed\/refractory aggressive B cell lymphomas","volume":"28","author":"Riedell","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"5","key":"10.1016\/j.jtct.2025.10.025_bib0018","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1182\/bloodadvances.2024014164","article-title":"Lisocabtagene maraleucel for relapsed\/refractory large B-cell lymphoma: a cell therapy consortium real-world analysis","volume":"9","author":"Riedell","year":"2025","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.jtct.2025.10.025_bib0019","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood.2023020854","article-title":"Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001","volume":"143","author":"Abramson","year":"2024","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jtct.2025.10.025_bib0020","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2025.10.025_bib0021","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.jtct.2025.10.025_bib0022","first-page":"2307","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2025.10.025_bib0023","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"for the ZUMA-7 Investigators and Kite Members. Survival with axicabtagene ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jtct.2025.10.025_bib0024","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.22.00642","article-title":"Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial","volume":"41","author":"Laetsch","year":"2023","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.jtct.2025.10.025_bib0025","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood.2023021567","article-title":"Durable response after tisagenlecleucel in adults with relapsed\/refractory follicular lymphoma: ELARA trial update","volume":"143","author":"Dreyling","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2025.10.025_bib0026","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13045-022-01379-0","article-title":"Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study","volume":"15","author":"Shah","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"suppl 16","key":"10.1016\/j.jtct.2025.10.025_bib0027","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2024.42.16_suppl.7013","volume":"41","author":"Kamdar","year":"2024","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2025.10.025_bib0028","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1182\/blood-2023-180952","article-title":"Lisocabtagene maraleucel as second-line therapy for R\/R large B-cell lymphoma in patients not intended for hematopoietic stem cell transplant: final analysis of the phase 2 PILOT study","volume":"142","author":"Sehgal","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2025.10.025_bib0029","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1182\/blood-2024-200204","article-title":"Five-year survival of patients (pts) from Transcend NHL 001 (TRANSCEND) supports curative potential of lisocabtagene maraleucel (liso-cel) in relapsed or refractory (R\/R) large B-cell lymphoma (LBCL)","volume":"144","author":"Abramson","year":"2024","journal-title":"Blood"},{"issue":"2 suppl","key":"10.1016\/j.jtct.2025.10.025_bib0030","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.1016\/j.jtct.2025.01.319","volume":"31","author":"Wang","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2025.10.025_bib0031","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1182\/blood-2024-198509","article-title":"Lisocabtagene maraleucel (liso-cel) in patients (pts) with relapsed or refractory (R\/R) follicular lymphoma (FL): Transcend FL 2-year follow-up","volume":"144","author":"Nastoupil","year":"2024","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2025.10.025_bib0032","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1182\/bloodadvances.2024014171","article-title":"Access barriers to anti-CD19+ CART therapy for NHL across a community transplant and cellular therapy network","volume":"9","author":"Battiwalla","year":"2025","journal-title":"Blood Adv"},{"issue":"18","key":"10.1016\/j.jtct.2025.10.025_bib0033","doi-asserted-by":"crossref","first-page":"4727","DOI":"10.1182\/bloodadvances.2024015634","article-title":"Inequalities in CAR T-cell therapy access for US patients with relapsed\/refractory DLBCL: a SEER-Medicare data analysis","volume":"9","author":"Chung","year":"2025","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.jtct.2025.10.025_bib0034","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.jtct.2023.06.012","article-title":"ASTCT clinical practice recommendations for transplantation and cellular therapies in diffuse large B cell lymphoma","volume":"29","author":"Epperla","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"12","key":"10.1016\/j.jtct.2025.10.025_bib0035","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/j.bbmt.2019.08.015","article-title":"Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed\/refractory aggressive B cell non-Hodgkin lymphoma: an expert panel opinion from the American Society for Transplantation and Cellular Therapy","volume":"25","author":"Jain","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2025.10.025_bib0036","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jtct.2023.10.022","article-title":"Chimeric antigen receptor T cell therapy for myeloma: where are we now and what is needed to move chimeric antigen receptor T cells forward to earlier lines of therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy","volume":"30","author":"Anderson","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"10.1016\/j.jtct.2025.10.025_bib0037","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jtct.2022.06.019","article-title":"Role of CD19 chimeric antigen receptor T cells in second-line large B cell lymphoma: lessons from phase 3 trials. An expert panel opinion from the American Society for Transplantation and Cellular Therapy","volume":"28","author":"Perales","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"24","key":"10.1016\/j.jtct.2025.10.025_bib0038","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1200\/JCO-25-00399","article-title":"Lisocabtagene maraleucel versus standard of care for second-line relapsed\/refractory large B-cell lymphoma: 3-year follow-up from the randomized, phase III TRANSFORM study","volume":"43","author":"Kamdar","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2025.10.025_bib0039","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ejca.2022.08.019","article-title":"Transplant-ineligible but chimeric antigen receptor T-cells eligible: a real and relevant population","volume":"175","author":"Vic","year":"2022","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.jtct.2025.10.025_bib0040","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1038\/s41591-023-02572-5","article-title":"Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial","volume":"29","author":"Houot","year":"2023","journal-title":"Nat Med"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2025.10.025_bib0041","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1182\/blood-2023-184862","article-title":"Lisocabtagene maraleucel in relapsed\/refractory large B-cell lymphoma: real world analysis from the cell therapy consortium","volume":"142","author":"Riedell","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2025.10.025_bib0042","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1182\/blood-2022-163750","article-title":"Impact of age on outcomes after CD19 directed CAR T cell therapy for large B cell lymphomas: real world experience from the Center for International Blood & Marrow Transplant Research (CIBMTR)","volume":"140","author":"Mirza","year":"2022","journal-title":"Blood"},{"issue":"2 suppl","key":"10.1016\/j.jtct.2025.10.025_bib0043","doi-asserted-by":"crossref","first-page":"S192","DOI":"10.1016\/j.jtct.2023.12.249","article-title":"Real-world comparison of lisocabtagene maraleucel (liso-cel) and axicabtagene ciloleucel (axi-cel): efficacy & toxicity","volume":"30","author":"Portuguese","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2025.10.025_bib0044","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1182\/blood-2023-180242","article-title":"Multicenter, real-world study in patients with R\/R large B-cell lymphoma (LBCL) who received lisocabtagene maraleucel (liso-cel) in the United States (US)","volume":"142","author":"Crombie","year":"2023","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jtct.2025.10.025_bib0045","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/s41409-025-02541-1","article-title":"Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study","volume":"60","author":"Kharfan-Dabaja","year":"2025","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2025.10.025_bib0046","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3324\/haematol.2019.243246","article-title":"Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed\/refractory large B-cell lymphoma","volume":"106","author":"Lin","year":"2021","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.jtct.2025.10.025_bib0047","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1002\/ajh.27381","article-title":"Anti-CD19 chimeric antigen receptor T-cell therapy in older patients with relapsed or refractory large B-cell lymphoma: a multicenter study","volume":"99","author":"Tun","year":"2024","journal-title":"Am J Hematol"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2025.10.025_bib0048","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1182\/blood-2024-201822","article-title":"Safety and efficacy of chimeric antigen receptor T-cell therapy in octogenarian patients (aged \u2265 80) with relapsed or refractory (R\/R) large B-cell lymphoma (LBCL)","volume":"144","author":"Lee","year":"2024","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.jtct.2025.10.025_bib0049","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1080\/10428194.2024.2387731","article-title":"CAR T-cells in very elderly (\u2265 80 years) lymphoma patients: a DESCAR-T analysis","volume":"65","author":"Menez","year":"2024","journal-title":"Leuk Lymphoma"},{"issue":"14","key":"10.1016\/j.jtct.2025.10.025_bib0050","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1182\/bloodadvances.2023010003","article-title":"Prospective geriatric assessment and geriatric consultation in CAR T-cell therapy for older patients with lymphoma","volume":"7","author":"Lin","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2025.10.025_bib0051","series-title":"Presented at: European Hematology Association (EHA) 2024 Congress","article-title":"Real-world assessment of anti-CD19 CAR-T cells in patients aged 75 years and older with relapsed or refractory large B cell lymphoma: a LYSA study from the DESCAR-T registry","author":"Guffroy","year":"2024"},{"issue":"6","key":"10.1016\/j.jtct.2025.10.025_bib0052","doi-asserted-by":"crossref","first-page":"916","DOI":"10.3109\/0284186X.2014.978367","article-title":"on behalf of the Swedish Lymphoma Study Group. The impact of age on survival of diffuse large B-cell lymphoma \u2013 a population-based study","volume":"54","author":"Hedstr\u00f6m","year":"2015","journal-title":"Acta Oncol"},{"issue":"14","key":"10.1016\/j.jtct.2025.10.025_bib0053","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1182\/bloodadvances.2024012727","article-title":"Optimization of older adults by a geriatric assessment\u2013guided multidisciplinary clinic before CAR T-cell therapy","volume":"8","author":"Yates","year":"2024","journal-title":"Blood Adv"},{"issue":"27","key":"10.1016\/j.jtct.2025.10.025_bib0054","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.19.02103","article-title":"Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity","volume":"38","author":"Jacobson","year":"2020","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2025.10.025_bib0055","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1182\/blood-2021-149679","article-title":"Real-world outcomes of axicabtagene ciloleucel (axi-cel) for the treatment of large B-cell lymphoma (LBCL): impact of age and specific organ dysfunction","volume":"138","author":"Locke","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.10.025_bib0056","series-title":"BREYANZI\u00ae (lisocabtagene maraleucel) [package insert]","year":"2025"},{"key":"10.1016\/j.jtct.2025.10.025_bib0057","series-title":"YESCARTA\u00ae (axicabtagene ciloleucel) [package insert]","year":"2025"},{"issue":"7","key":"10.1016\/j.jtct.2025.10.025_bib0058","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.3324\/haematol.2021.280009","article-title":"Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma","volume":"107","author":"Steiner","year":"2022","journal-title":"Haematologica"},{"issue":"18","key":"10.1016\/j.jtct.2025.10.025_bib0059","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/j.jacc.2021.08.044","article-title":"Adverse cardiovascular and pulmonary events associated with chimeric antigen receptor T-cell therapy","volume":"78","author":"Goldman","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.jtct.2025.10.025_bib0060","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/bjh.19497","article-title":"Atrial arrhythmias following CAR-chimeric antigen receptor T-cell therapy: incidence, risk factors and biomarker profile","volume":"205","author":"Shouval","year":"2024","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.jtct.2025.10.025_bib0061","first-page":"18","article-title":"Cardiac and inflammatory biomarker differences in adverse cardiac events after chimeric antigen receptor T-cell therapy: an exploratory study","volume":"9","author":"Lee","year":"2023","journal-title":"Cardiooncology"},{"issue":"7","key":"10.1016\/j.jtct.2025.10.025_bib0062","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/bloodadvances.2024014488","article-title":"Pretreatment pulmonary function testing has limited utility in B-cell lymphoma treated with CD19 CAR T cells","volume":"9","author":"Sdayoor","year":"2025","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.jtct.2025.10.025_bib0063","article-title":"Outcomes of CD19-targeted chimeric antigen receptor T cell therapy for patients with reduced renal function including dialysis","volume":"28","author":"Wood","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"10.1016\/j.jtct.2025.10.025_bib0064","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-008975","article-title":"Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma","volume":"12","author":"Bharadwaj","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.jtct.2025.10.025_bib0065","first-page":"651","article-title":"Predictors and implications of renal injury after CD19 chimeric antigen receptor T-cell therapy","volume":"110","author":"Boardman","year":"2025","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.jtct.2025.10.025_bib0066","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1111\/bjh.19152","article-title":"Real-world analysis of safety and efficacy of CAR T-cell therapy in lymphoma patients with decreased kidney function","volume":"204","author":"Mamlouk","year":"2024","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.jtct.2025.10.025_bib0067","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.bbmt.2020.02.012","article-title":"Acute kidney injury after CAR-T cell therapy: low incidence and rapid recovery","volume":"26","author":"Gutgarts","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2025.10.025_bib0068","doi-asserted-by":"crossref","first-page":"4506","DOI":"10.1182\/blood-2024-207616","article-title":"Impact of pre-treatment liver-related factors on clinical outcomes after CAR T-cell therapy for lymphoma","volume":"144","author":"Lionel","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.10.025_bib0069","unstructured":"Holmberg LA, Sandmaier BM. Determining eligibility for autologous hematopoietic cell transplantation. Updated November 14, 2024. Available at:https:\/\/www.uptodate.com\/contents\/determining-eligibility-for-autologous-hematopoietic-cell-transplantation. Accessed June 2025."},{"issue":"3","key":"10.1016\/j.jtct.2025.10.025_bib0070","article-title":"Incidence and management of effusions before and after CD19-directed chimeric antigen receptor (CAR) T cell therapy in large B cell lymphoma","volume":"27","author":"Mirza","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"10.1016\/j.jtct.2025.10.025_bib0071","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.jtct.2024.07.018","article-title":"Best practice considerations by the American Society of Transplant and Cellular Therapy: infection prevention and management after chimeric antigen receptor T cell therapy for hematological malignancies","volume":"30","author":"Shahid","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"10.1016\/j.jtct.2025.10.025_bib0072","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.2019004000","article-title":"How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies","volume":"136","author":"Hill","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2025.10.025_bib0073","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1182\/blood-2024-198053","article-title":"Impact of pre-existing mental health disorders (MHD) on CAR T-cell therapy outcomes in patients with large B-cell lymphoma","volume":"144","author":"Gouni","year":"2024","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2025.10.025_bib0074","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1016\/j.clml.2024.09.010","article-title":"Sociodemographic factors influencing access to chimeric antigen T-cell receptor therapy for patients with non-Hodgkin lymphoma","volume":"25","author":"Khare","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.jtct.2025.10.025_bib0075","article-title":"Efficacy and toxicity of CD19 chimeric antigen receptor T cell therapy for lymphoma in solid organ transplant recipients: a systematic review and meta-analysis","volume":"30","author":"Yamshon","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"10.1016\/j.jtct.2025.10.025_bib0076","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/bjh.18828","article-title":"Real-world evidence of the safety and survival with CD19 CAR-T cell therapy for relapsed\/refractory solid organ transplant-related PTLD","volume":"202","author":"McKenna","year":"2023","journal-title":"Br J Haematol"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2025.10.025_bib0077","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1182\/blood-2024-199702","volume":"144","author":"Ahmed","year":"2024","journal-title":"Blood"},{"issue":"16 suppl","key":"10.1016\/j.jtct.2025.10.025_bib0078","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1200\/JCO.2024.42.16_suppl.2006","article-title":"A pilot study of axicabtagene ciloleucel (axi-cel) for relapsed\/refractory primary and secondary central nervous system lymphoma (PCNSL and SCNSL)","volume":"42","author":"Nayak","year":"2024","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.jtct.2025.10.025_bib0079","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1182\/bloodadvances.2021004554","article-title":"Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy","volume":"5","author":"Miller","year":"2021","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.jtct.2025.10.025_bib0080","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1182\/bloodadvances.2021005747","article-title":"Prevalence and variation of CHIP in patients with aggressive lymphomas undergoing CD19-directed CAR T-cell treatment","volume":"6","author":"Teipel","year":"2022","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.jtct.2025.10.025_bib0081","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1158\/2643-3230.BCD-21-0177","article-title":"Clonal hematopoiesis is associated with increased risk of severe neurotoxicity in axicabtagene ciloleucel therapy of large B-cell lymphoma","volume":"3","author":"Saini","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"6","key":"10.1016\/j.jtct.2025.10.025_bib0082","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/ajh.26915","article-title":"Clonal hematopoiesis of indeterminate potential and clonal cytopenias of undetermined significance: 2023 update on clinical associations and management recommendations","volume":"98","author":"Mangaonkar","year":"2023","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.jtct.2025.10.025_bib0083","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1200\/JCO.23.01097","article-title":"Recent bendamustine treatment before apheresis has a negative impact on outcomes in patients with large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy","volume":"42","author":"Iacoboni","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jtct.2025.10.025_bib0084","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/JCO.21.02370","article-title":"Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.jtct.2025.10.025_bib0085","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas","volume":"26","author":"Deng","year":"2020","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.jtct.2025.10.025_bib0086","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.ccell.2021.06.012","article-title":"The role of exhaustion in CAR T cell therapy","volume":"39","author":"Delgoffe","year":"2021","journal-title":"Cancer Cell"},{"issue":"20","key":"10.1016\/j.jtct.2025.10.025_bib0087","doi-asserted-by":"crossref","first-page":"5346","DOI":"10.1182\/bloodadvances.2023012549","article-title":"Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel","volume":"8","author":"Ahmed","year":"2024","journal-title":"Blood Adv"},{"issue":"16 suppl","key":"10.1016\/j.jtct.2025.10.025_bib0088","doi-asserted-by":"crossref","first-page":"7026","DOI":"10.1200\/JCO.2025.43.16_suppl.7026","article-title":"Optimizing post\u2013chimeric antigen receptor (CAR) T cell monitoring: evidence across lisocabtagene maraleucel (liso-cel) pivotal clinical trials and real-world experience","volume":"43","author":"Kamdar","year":"2025","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.jtct.2025.10.025_bib0089","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","article-title":"A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy","volume":"30","author":"Cordas Dos Santos","year":"2024","journal-title":"Nat Med"},{"issue":"30","key":"10.1016\/j.jtct.2025.10.025_bib0090","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1200\/JCO.23.02786","article-title":"Five-year follow-up of standard-of-care axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR T Consortium","volume":"42","author":"Jain","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2025.10.025_bib0091","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41591-023-02767-w","article-title":"Unanswered questions following reports of secondary malignancies after CAR-T cell therapy","volume":"30","author":"Levine","year":"2024","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.jtct.2025.10.025_bib0092","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.jtct.2024.06.027","article-title":"Subsequent malignancies after CD19-targeted chimeric antigen receptor T cells in patients with lymphoma","volume":"30","author":"Lorenc","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.jtct.2025.10.025_bib0093","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","article-title":"T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy","volume":"30","author":"Ghilardi","year":"2024","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.jtct.2025.10.025_bib0094","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1038\/s41409-021-01270-5","article-title":"Autologous stem cell transplantation for post-transplant lymphoproliferative disorders after solid organ transplantation: a retrospective analysis from the Lymphoma Working Party of the EBMT","volume":"56","author":"Eyre","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2025.10.025_bib0095","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bbmt.2019.08.021","article-title":"Hematopoietic stem cell transplantation in solid organ recipients with emphasis on transplant complications: a nationwide retrospective survey on behalf of the Japan Society for Hematopoietic Stem Cell Transplantation Transplant Complications Working Group","volume":"26","author":"Shinohara","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"14","key":"10.1016\/j.jtct.2025.10.025_bib0096","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1200\/JCO.2016.71.6712","article-title":"Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma","volume":"35","author":"Gibson","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2025.10.025_bib0097","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1053\/j.seminhematol.2024.01.011","article-title":"Clonal hematopoiesis in the setting of hematopoietic cell transplantation","volume":"61","author":"Gibson","year":"2024","journal-title":"Semin Hematol"},{"issue":"12","key":"10.1016\/j.jtct.2025.10.025_bib0098","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/j.bbmt.2015.08.004","article-title":"Hematopoietic cell transplantation after solid organ transplantation","volume":"21","author":"Doney","year":"2015","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725015283?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725015283?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T05:39:54Z","timestamp":1773985194000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725015283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":98,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2666636725015283"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.10.025","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Who Is Eligible for Chimeric Antigen Receptor T Cell Therapy? Expert Perspectives on Overcoming Referral Barriers","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.10.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of the American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}